Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.43 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990302 | 0.85 | GRM5 (0.71) | GRM5PRMT5WDR77CCNCCDK8 | |
| SCHEMBL991465 | 0.83 | GRM5 (0.75) | GRM5PRMT5WDR77TRPC3TRPC6 | |
| SCHEMBL4515090 | 0.79 | GRM5 (0.74) | GRM5 | |
| SCHEMBL4528122 | 0.76 | GRM5 (0.75) | GRM5 | |
| SCHEMBL4528131 | 0.76 | GRM5 (0.75) | GRM5 | |
| SCHEMBL992193 | 0.76 | GRM5 (0.72) | GRM5PRMT5WDR77 | |
| SCHEMBL5909354 | 0.75 | CCNC (0.56) | HSP90AA1HSP90AB1PRMT5WDR77CCNC | |
| SCHEMBL16870869 | 0.74 | GRM5 (1.00) | GRM5 | |
| SCHEMBL990397 | 0.74 | GRM5 (0.68) | GRM5PRMT5WDR77 | |
| SCHEMBL4530469 | 0.73 | GRM5 (0.52) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GRM5 680/4885HSP90AA1 4384/4885HSP90AB1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.